<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152956</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD006-01</org_study_id>
    <nct_id>NCT02152956</nct_id>
  </id_info>
  <brief_title>Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS</brief_title>
  <official_title>A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase 1/2, dose-escalation study, is to determine the maximum
      tolerated dose level of flotetuzumab (MGD006) in patients with AML whose disease is not
      expected to benefit from cytotoxic chemotherapy. Studies will also be done to see how the
      drug acts in the body (pharmacokinetics [PK], pharmacodynamics) and to evaluate potential
      anti-tumor activity of flotetuzumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, multi-dose, single-arm, multi-center, Phase 1/2, dose-escalation study to define
      a maximum tolerated dose and schedule (MTDS), describe preliminarily safety, and to assess
      PK, immunogenicity, immunomodulatory activity, and potential anti-tumor activity of
      flotetuzumab in patients with AML whose disease is not expected to benefit from cytotoxic
      chemotherapy.

      This study is designed in three segments: the Single Patient Dose Escalation Segment,
      followed by the Multi-Patient Dose Escalation Segment and the MTDS Expansion Cohort Segment.

      The Multi-Patient Dose Escalation Segment will employ a classical 3+3 scheme to examine a
      series of increasing dose escalations in cohorts of patients with AML.

      Any Dose Escalation Cohort not exceeding the maximum tolerated dose may be expanded to
      include up to 15 patients for further evaluation of the safety, PK, and preliminary
      anti-tumor activity of flotetuzumab. Once the MTDS is established, the cohort of patients
      treated at that dose/schedule or a lower dose, will be expanded with the addition of up to
      120 AML patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2014</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose limiting toxicity</measure>
    <time_frame>Cycle 1 of a 28 day cycle.</time_frame>
    <description>• Maximum Tolerated Dose/Schedule: the MTDS will be defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is &lt; 33% during the first cycle of MGD006 treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-leukemic activity</measure>
    <time_frame>Every 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the pharmacokinetics (PK) of flotetuzumab</measure>
    <time_frame>Cycle 1 through end of treatment (28 day cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-drug antibody</measure>
    <time_frame>Cycle 1 through end of treatment (28 day cycles)</time_frame>
    <description>ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from first dose to death from any cause; assessed up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">179</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Flotetuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD123 x CD3 bispecific DART® antibody</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flotetuzumab</intervention_name>
    <description>Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.</description>
    <arm_group_label>Flotetuzumab</arm_group_label>
    <other_name>MGD006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of primary or secondary AML [any subtype except acute
             promyelocytic leukemia (APL)] according to World Health Organization (WHO)
             classification

          -  Patients with AML must be unlikely to benefit from recommended standard of care
             defined by any one of the following criteria:

             a. AML refractory to ≥ 2 (or ≥ 1 for patients &gt; 65 years of age) induction attempts,
             including but not limited to the following:

             i. AML refractory to ≥ 1 intensive induction attempt(s), per institution, including
             high- and standard-dose cytarabine ± an anthracyclines/anthracenedione ± an
             anti-metabolite with or without growth factor or targeted therapy,

        ii. for adults who are age 75 years or older, or who have comorbidities that preclude use
        of intensive induction chemotherapy, AML refractory to ≥ 2 lower intensity induction
        attempts including Bcl-2 or Hedgehog inhibitors with azacitidine/decitabine/LDAC or
        available targeted therapies such as FLT3/IDH1/IDH2/anti-CD33 antibodies;

        b. AML in 1st relapse with initial CR duration &lt; 6 months,

        c. a maximum of up to 2 prior salvage attempts is allowed.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Life expectancy of at least 4 weeks

          -  Peripheral blast count &lt;/= 20,000/mm3 at the time of registration

          -  Acceptable laboratory parameters and adequate organ reserve

        Exclusion Criteria:

          -  History of allogeneic stem cell transplantation.

          -  Prior treatment with an anti-CD123-directed agent, with the exception of patients with
             relapsed disease after flotetuzumab treatment

          -  Need for concurrent other cytoreductive chemotherapy

          -  Any prior history of or suspected current autoimmune disorders (with the exception of
             vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid
             clinically and by laboratory testing)

          -  Second primary malignancy that requires active therapy. Adjuvant hormonal therapy is
             allowed.

          -  Antitumor therapy or investigational agent within 14 days or 5 half-lives of Cycle 1
             Day 1

          -  Requirement, at the time of study entry, for concurrent steroids &gt; 10 mg/day of oral
             prednisone or the equivalent, except steroid inhaler, nasal spray or ophthalmic
             solution

          -  Use of immunosuppressant medications in the 2 weeks of Cycle 1 Day 1

          -  Use of granulocyte colony stimulating or granulocyte-macrophage colony stimulating
             factor in the 2 weeks of Cycle 1 Day 1

          -  Known central nervous system (CNS) leukemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John DiPersio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Davidson-Moncada, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Vey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Tran</last_name>
    <email>trank@Macrogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Yu</last_name>
      <phone>626-256-4672</phone>
      <phone_ext>83524</phone_ext>
      <email>diyu@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Aldoss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Wiegand</last_name>
      <phone>858-822-6396</phone>
      <email>mwiegand@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Bishop</last_name>
      <phone>858-822-1960</phone>
      <email>e2Bishop@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Wieduwilt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Nattinger</last_name>
      <phone>415-514-4805</phone>
      <email>Caroline.Nattinger@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Sayre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gleason</last_name>
      <phone>404-778-4334</phone>
      <email>Shannon.gleason@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Martha Arellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lela Lartey</last_name>
      <phone>312-695-1377</phone>
      <email>emanuela.lartey@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Altman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Kflu</last_name>
      <phone>410-328-9416</phone>
      <email>veronica.kflu@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Ashkan Emadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Taralunga</last_name>
      <phone>734-232-0773</phone>
      <email>roxanat@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Petit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayan Gasanli</last_name>
      <phone>314-747-2449</phone>
      <email>agasanli@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Uy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John DiPersio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison McKinney</last_name>
      <phone>919-966-4432</phone>
      <email>allison_mckinney@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Mathew C. Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Harry Erba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Root</last_name>
      <phone>216-444-3576</phone>
      <email>ROOTK2@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Eric Wiedenfeld</last_name>
      <phone>216-445-0003</phone>
      <email>wiedene@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anjali Advani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neysa Dagostino, RN, OCN</last_name>
      <phone>503-215-2608</phone>
      <email>neysa.dagostino@providence.org</email>
    </contact>
    <investigator>
      <last_name>John Godwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dino Francescutti</last_name>
      <phone>615-875-9980</phone>
      <email>dino.francescutti@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Michael T Byrne, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa J. McFarland</last_name>
      <phone>713-745-1216</phone>
      <email>MJMacFarland@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Farhad Ravandi-Kashani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherise Athay</last_name>
      <email>cathay@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Ronald Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn Gauger</last_name>
      <phone>414-805-4587</phone>
      <email>kgauger@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Michaelis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Veuillen</last_name>
      <email>veuillenc@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Vey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Robert</last_name>
      <email>lea.robert@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiba El Sayadi Bizri</last_name>
      <email>H.BIZRIELSAYADI@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Gyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Max Langner</last_name>
      <email>max.langner@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Martin Wermke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und II, Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzbur</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johana Reif</last_name>
      <email>Reif_J@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Max Topp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Frabetti</last_name>
      <email>federica.frabetti2@studio.unibo.it</email>
    </contact>
    <investigator>
      <last_name>Stefania Paolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Vita-Salute San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Trinca</last_name>
      <email>trinca.stefania@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erna Helmantel</last_name>
      <email>e.helmantel@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Gerwin Huls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Longergan</last_name>
      <email>s.lonergan@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Bob Lowenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>leukemia</keyword>
  <keyword>myelogenous</keyword>
  <keyword>myeloid</keyword>
  <keyword>refractory</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

